WallStreetZenWallStreetZen

NASDAQ: BYSI
Beyondspring Inc Stock

$1.09+0.02 (+1.87%)
Updated Feb 23, 2024
BYSI Price
$1.09
Fair Value Price
-$0.61
Market Cap
$42.53M
52 Week Low
$0.65
52 Week High
$2.03
P/E
-1.54x
P/B
-2.35x
P/S
29.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.55M
Earnings
-$27.51M
Gross Margin
100%
Operating Margin
-1,783.55%
Profit Margin
-1,774.8%
Debt to Equity
-2.63
Operating Cash Flow
N/A
Beta
0.93
Next Earnings
Feb 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BYSI Overview

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BYSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BYSI ($1.09) is overvalued by 279.84% relative to our estimate of its Fair Value price of -$0.61 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BYSI ($1.09) is not significantly undervalued (279.84%) relative to our estimate of its Fair Value price of -$0.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BYSI due diligence checks available for Premium users.

Be the first to know about important BYSI news, forecast changes, insider trades & much more!

BYSI News

Valuation

BYSI fair value

Fair Value of BYSI stock based on Discounted Cash Flow (DCF)
Price
$1.09
Fair Value
-$0.61
Undervalued by
279.84%
BYSI ($1.09) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BYSI ($1.09) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BYSI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.54x
Industry
16.16x
Market
33.56x

BYSI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-2.35x
Industry
6.12x

BYSI's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BYSI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$32.9M
Liabilities
$47.6M
Debt to equity
-2.63
BYSI's short-term assets ($25.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BYSI's long-term liabilities ($40.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BYSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BYSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

BYSI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BYSI$42.53M+1.87%-1.54x-2.35x
LTRN$42.50M+1.03%-2.79x0.94x
HCWB$42.45M0.00%-2.11x1.78x
ACXP$43.37M+0.64%-3.00x11.02x
INTS$43.46M+5.67%-1.30x2.73x

Beyondspring Stock FAQ

What is Beyondspring's quote symbol?

(NASDAQ: BYSI) Beyondspring trades on the NASDAQ under the ticker symbol BYSI. Beyondspring stock quotes can also be displayed as NASDAQ: BYSI.

If you're new to stock investing, here's how to buy Beyondspring stock.

What is the 52 week high and low for Beyondspring (NASDAQ: BYSI)?

(NASDAQ: BYSI) Beyondspring's 52-week high was $2.03, and its 52-week low was $0.65. It is currently -46.31% from its 52-week high and 66.92% from its 52-week low.

How much is Beyondspring stock worth today?

(NASDAQ: BYSI) Beyondspring currently has 39,015,476 outstanding shares. With Beyondspring stock trading at $1.09 per share, the total value of Beyondspring stock (market capitalization) is $42.53M.

Beyondspring stock was originally listed at a price of $16.80 in Mar 9, 2017. If you had invested in Beyondspring stock at $16.80, your return over the last 6 years would have been -93.51%, for an annualized return of -36.61% (not including any dividends or dividend reinvestments).

How much is Beyondspring's stock price per share?

(NASDAQ: BYSI) Beyondspring stock price per share is $1.09 today (as of Feb 23, 2024).

What is Beyondspring's Market Cap?

(NASDAQ: BYSI) Beyondspring's market cap is $42.53M, as of Feb 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beyondspring's market cap is calculated by multiplying BYSI's current stock price of $1.09 by BYSI's total outstanding shares of 39,015,476.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.